Manuela Schmid
CSL Behring LLC
1020 1st Avenue 11.01.2024 nr RKU-4/4
19406-1310 King Of Prussia
AMEERIKA ÜHENDRIIGID
OTSUS
Ravimi kliinilise uuringu loa andmiseks Euroopa Parlamendi ja nõukogu määruse (EL) nr
536/2014 (määrus (EL) 536/2014) alusel
Uuringu sponsor CSL Behring LLC esitas 30.10.2023 Ravimiametile taotluse ravimi kliinilise
uuringu teostamiseks määruse (EL) 536/2014 artikli 5 (1) ja ravimiseaduse (RavS) § 991 lõikes
1 sätestatud tingimustel.
Tuginedes määruse (EL) 536/2014 artiklile 8, hindamisaruande I ja II osaga hõlmatud aspekte
hinnates, otsustab Ravimiamet ravimiseaduse § 996 lg 1 punkti 1 ja lõike 3 alusel
anda uuringu sponsorile CSL Behring LLC loa ravimi kliinilise uuringu läbiviimiseks
vastavalt esitatud uuringuplaanile nr CSL300_2301 järgmistel tingimustel:
uuringuplaani number: CSL300_2301 (Muudatus 1 kuupäevaga 2. mai 2023)
uuringu referentsnumber: 23-034
uuringu nimetus: „A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-
Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the
Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease
Undergoing Dialysis“
uuringu sponsor: CSL Behring LLC
uuritavate arv Eestis: 21
uuringu algus: jaanuar 2024
vastutavad uurijad ja uuringukeskused:
- Dr Kadri Lilienthal, sihtasutus Põhja-Eesti Regionaalhaigla, J. Sütiste tee 19, 13419
Tallinn, Eesti
- Dr Madis Ilmoja, Lääne-Tallinna Keskhaigla AS, Paldiski mnt 68, 10617 Tallinn, Eesti
- Dr Mai Ots-Rosenberg, Tartu Ülikooli Kliinikum, L. Puusepa tn 8, 50406 Tartu, Eesti
Nooruse 1 / 50411 Tartu / 737 4140 /
[email protected] / www.ravimiamet.ee / Registrikood 70003477
Vaide käesolevale otsusele saab esitada Ravimiametile 30 päeva jooksul arvates otsuse
teatavaks tegemisest vastavalt haldusmenetluse seaduse § 71 lõikele 1. Kui otsuse saaja soovib
otsust vaidlustada halduskohtus, võib ta vastavalt halduskohtumenetluse seadustiku § 7 lõikele
1 ja § 46 lõikele 1 esitada kaebuse otsuse peale Tartu Halduskohtule 30 päeva jooksul otsuse
teatavaks tegemisest arvates.
Lugupidamisega
(allkirjastatud digitaalselt)
Katrin Kiisk
Peadirektor
2 (2)
Manuela Schmid
CSL Behring LLC
1020 1st Avenue 11.01.2024 nr RKU-4/4
19406-1310 King Of Prussia
UNITED STATES
DECISION
to grant authorisation for clinical trial on the basis of Regulation (EU) No 536/2014 of the
European Parliament and of the council
State Agency of Medicines has received the application from sponsor CSL Behring LLC on
30.10.2023 to conduct a clinical trial under the conditions stipulated in Regulation (EU) No
536/2014 art 5 (1) and § 991 (1) of Estonian Medicinal Products Act (MPA).
Based on art 8 of Regulation (EU) No 536/2014, considering the aspects covered by Part I and
Part II of the assessment report, on the basis of § 996 section 1 p 1 and (3) of Medicinal Product
Act
State Agency of Medicines has decided to give the approval to conduct the clinical study
protocol no CSL300_2301 under the following conditions:
protocol no: CSL300_2301 (Amendment 1, dated May 02, 2023)
full title of the trial: A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-
Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the
Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease
Undergoing Dialysis
sponsor of the trial: CSL Behring LLC
number of subjects in Estonia: 21
starting date: January 2024
principal investigators and study locations:
- Dr Kadri Lilienthal, North Estonia Medical Centre Foundation, J. Sütiste tee 19, 13419
Tallinn, Estonia
- Dr Madis Ilmoja, Lääne-Tallinna Keskhaigla AS, Paldiski mnt 68, 10617 Tallinn,
Estonia
- Dr Mai Ots-Rosenberg, Tartu University Hospital, L. Puusepa tn 8, 50406 Tartu,
Estonia
Nooruse 1 / 50411 Tartu / 737 4140 /
[email protected] / www.ravimiamet.ee / Registrikood 70003477
The addressee may file a challenge with State Agency of Medicines within 30 days as of the
day when the addressee became or should have become aware of the decision as prescribed in
Code of Administrative Procedure § 71(1). If the addressee wishes to have the decision to
annulled by the administrative court, he or she may submit a complaint to the Tartu
Administrative Court as prescribed in § 7(1) and § 46(1) of the Code of Administrative Court
Procedure within 30 days after the date on which the decision was notified to the applicant.
(digitally signed)
Katrin Kiisk
Director General
2 (2)